Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development

被引：2
|
作者：
Jin, Yujin
Heo, Kyung-Sun [1 ]
机构：
[1] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
来源：
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY | 2023年 / 27卷 / 04期
基金：
新加坡国家研究基金会;
关键词：
Drug targeting; Hepatitis; Metabolic syndrome; Non-alcoholic fatty liver disease; LIPID-ACCUMULATION; MOUSE MODEL; ER STRESS; INFLAMMATION; APOPTOSIS; ACTIVATION; FIBROSIS; PATHWAY; CANCER; STEATOHEPATITIS;
D O I：
10.4196/kjpp.2023.27.4.299
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is a complex disorder characterized by the accumulation of fat in the liver in the absence of excessive alcohol consumption. It is one of the most common liver diseases worldwide, affecting approximately 25% of the global population. It is closely associated with obesity, type 2 diabetes, and metabolic syndrome. Moreover, NAFLD can progress to non-alcoholic steatohepatitis, which can cause liver cirrhosis, liver failure, and hepatocellular carcinoma. Currently, there are no approved drugs for the treatment of NAFLD. Therefore, the development of effective drugs is essential for NAFLD treatment. In this article, we discuss the experimental models and novel therapeutic targets for NAFLD. Additionally, we propose new strategies for the development of drugs for NAFLD.
引用
收藏
页码：299 / 310
页数：12
相关论文
共 50 条
  • [1] Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease
    Athyros, Vasilios G.
    Katsiki, Niki
    Karagiannis, Asterios
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 861 - 862
  • [2] Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
    Gruzdev, Stanislav Konstantinovich
    Podoprigora, Irina Viktorovna
    Gizinger, Oksana Anatolievna
    ARCHIVES OF MICROBIOLOGY, 2024, 206 (02)
  • [3] Macrophages and the development and progression of non-alcoholic fatty liver disease
    Alabdulaali, Bader
    Al-rashed, Fatema
    Al-Onaizi, Mohammed
    Kandari, Anwar
    Razafiarison, Joanna
    Tonui, Dorothy
    Williams, Michayla R.
    Bleriot, Camille
    Ahmad, Rasheed
    Alzaid, Fawaz
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] Platelets in Non-alcoholic Fatty Liver Disease
    Dalbeni, Andrea
    Castelli, Marco
    Zoncape, Mirko
    Minuz, Pietro
    Sacerdoti, David
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [6] Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
    Prikhodko, Veronika A.
    Bezborodkina, Natalia N.
    Okovityi, Sergey V.
    BIOMEDICINES, 2022, 10 (02)
  • [7] The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
    Li, Shu-Jing
    Liu, An-Bu
    Yu, Yuan-Yuan
    Ma, Jin-Hai
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [8] Treating inflammation to combat non-alcoholic fatty liver disease
    Wiering, Leke
    Tacke, Frank
    JOURNAL OF ENDOCRINOLOGY, 2023, 256 (01)
  • [9] Non-alcoholic fatty liver disease - clinical and histopathological aspects
    Popescu, Mihaela
    Popescu, Iulian Alin Silviu
    Stanciu, Mihaela
    Cazacu, Sergiu-Marian
    Ianosi, Nicolae-Gabriel
    Comanescu, Maria Victoria
    Singer, Cristina Elena
    Neagoe, Carmen-Daniela
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2016, 57 (04): : 1295 - 1302
  • [10] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
12345